Penn Vet Researchers Use Lipid Nanoparticles To "Melt Away" Pancreatic Cancer’s Protective Barrier And Enhance CAR T-Cell Success In Solid Tumors

University of Pennsylvania researchers used lipid nanoparticles to target CAFs, dissolving the protective matrix of pancreatic tumors and boosting CAR T success.

By: AXL Media

Published: Mar 31, 2026, 11:23 AM EDT

Source: Information for this report was sourced from University of Pennsylvania

Breaking the Barrier of Pancreatic Adenocarcinoma

Pancreatic cancer remains one of the most lethal malignancies due to its late-stage diagnosis and a unique biological defense system known as the desmoplastic matrix. This dense barrier of connective tissue and structural proteins acts as a physical shield, preventing immune cells and traditional therapies from reaching the tumor. Researchers at the University of Pennsylvania School of Veterinary Medicine have now identified a way to "melt away" this protection by targeting the cells that build it: cancer-associated fibroblasts (CAFs).

In Vivo Engineering via Lipid Nanoparticles

Traditional CAR T-cell therapy is a complex, multi-week process that requires removing a patient's T cells, engineering them in a laboratory, and reinfusing them. The Penn Vet team, led by Professor Ellen Puré, bypassed this hurdle by using lipid nanoparticles (LNPs)—the same delivery technology used in mRNA vaccines. These tiny fat-based particles carry genetic instructions directly to T cells already inside the patient's body, effectively turning the person's own immune system into a "living hardware" that produces cancer-fighting cells without the need for external manufacturing.

Laser Focused Targeting of FAP Cells

The researchers specifically equipped the T cells to identify Fibroblast Activation Protein (FAP), a marker found in high concentrations on the specialized fibroblasts that maintain the tumor's protective wall. Senior research investigator Khuloud Bajbouj described the approach as equipping the immune system with a "laser-focused" weapon. By targeting these support cells rather than the cancer cells directly, the therapy dismantles the infrastructure the tumor requires to survive and suppress the immune response.